For decades, Type 2 diabetes was described as a chronic, progressive, and irreversible disease. Patients were told they would need more medication over time, not less. That narrative has now been overturned by a convergence of clinical trial data, mechanistic research, and real-world remission programmes. The question is no longer whether Type 2 diabetes can be reversed — it is who can achieve it, and how.

Defining Remission: What the Science Says

The American Diabetes Association (ADA), in collaboration with the European Association for the Study of Diabetes (EASD) and Diabetes UK, published a consensus definition in 2021: remission is defined as an HbA1c below 6.5% (48 mmol/mol) sustained for at least three months, achieved without the use of glucose-lowering pharmacotherapy.^[1] This is a rigorous, measurable, clinical endpoint — not a subjective feeling of wellness.

It is important to distinguish remission from cure. Remission means the disease is not clinically active; the underlying metabolic vulnerability remains. Sustained lifestyle vigilance is required to maintain remission, and relapse is possible with weight regain or significant lifestyle deterioration.

The DiRECT Trial: Landmark Evidence

The most influential study in this space is the Diabetes Remission Clinical Trial (DiRECT), a cluster-randomised trial conducted across 49 primary care practices in the UK. Published in The Lancet in 2018, the trial assigned 306 participants with Type 2 diabetes (diagnosed within the previous 6 years) to either a structured weight management programme or standard care.^[2]

The weight management arm delivered a low-calorie total diet replacement (825–853 kcal/day) for 3–5 months, followed by structured food reintroduction and long-term support. At 12 months, 46% of intervention participants had achieved remission, compared with 4% in the control group. At 24 months, 36% of the intervention group maintained remission.^[3] Critically, remission rates correlated directly with the degree of weight loss: 86% of those who lost 15 kg or more achieved remission.

The 5-year follow-up data, published in 2024, showed that 13% of participants maintained remission at 5 years without any glucose-lowering medication — a result that would have been considered impossible by the medical consensus of a decade ago.^[4]

The Mechanism: The Twin Cycle Hypothesis

Professor Roy Taylor at Newcastle University proposed the twin cycle hypothesis to explain the pathophysiology of Type 2 diabetes reversal.^[5] The model identifies two interconnected vicious cycles:

• Liver cycle: Excess caloric intake leads to hepatic fat accumulation (non-alcoholic fatty liver). This causes hepatic insulin resistance, driving excess hepatic glucose output and raised fasting blood sugar. The liver also exports excess fat as VLDL triglycerides.
• Pancreas cycle: VLDL fat accumulates in the pancreas, impairing beta-cell function. Insulin secretion becomes insufficient relative to demand, completing the diabetic state.

When significant caloric restriction is achieved — typically through weight loss of 10–15% of body weight — ectopic fat is mobilised from both the liver and pancreas. Hepatic fat can fall within 7 days of caloric restriction. As intrapancreatic fat decreases, beta-cell function partially recovers, restoring first-phase insulin secretion.^[6]

Who Is Most Likely to Achieve Remission?

The DiRECT and DIRECT-Plus trials, along with mechanistic studies, identify several predictors of successful remission:

• Duration of diabetes: Those diagnosed within the preceding 6 years have the highest remission rates. Beta-cell recovery is more limited after prolonged hyperglycaemic stress.
• Degree of weight loss: A consistent dose-response relationship exists. Losing 5–10% of body weight improves glycaemic control; losing 15% or more achieves remission in the majority of eligible patients.
• Baseline HbA1c: Lower baseline HbA1c (closer to 7%) is associated with higher remission rates. Very high HbA1c (>10%) suggests more advanced beta-cell dysfunction.
• Absence of insulin use: Patients already on insulin have lower remission rates, suggesting more advanced disease.

Beyond Caloric Restriction: The Role of Lifestyle Medicine

Weight loss is the primary driver of remission, but the method of achieving it matters for sustainability. The PREDIMED-Plus trial demonstrated that a Mediterranean diet combined with physical activity and behavioural support produced significant HbA1c reductions and weight loss maintained at 3 years.^[7] Time-restricted eating (16:8 protocol) has shown HbA1c reductions comparable to caloric restriction in randomised trials, with improved patient adherence.^[8]

Progressive resistance training is a critically underutilised intervention. Skeletal muscle is the body’s largest glucose disposal site; increasing muscle mass through resistance exercise directly improves insulin sensitivity, independently of weight loss.^[9]

Dr. Ahmed’s Clinical Approach at SehaTalks

Our Diabetes Remission Programme is built on the evidence reviewed above. The protocol includes: comprehensive baseline metabolic assessment (HbA1c, fasting insulin, HOMA-IR, lipid panel, renal function, hepatic enzymes); a structured low-glycaemic nutritional protocol tailored to the individual; time-restricted eating guidance; progressive walking and resistance training; and HbA1c monitoring at 8-week intervals. The entire programme is delivered via telemedicine, removing geographic barriers to access.

Medications are reviewed and adjusted proactively at each stage — as weight loss proceeds and insulin sensitivity improves, most patients require dose reductions or complete discontinuation of glucose-lowering agents.

Key Takeaways

• Type 2 diabetes remission is clinically defined and scientifically achievable.
• The DiRECT trial demonstrated 46% remission at 12 months with structured weight management.
• The core mechanism is ectopic fat reduction in the liver and pancreas, restoring beta-cell function.
• Earlier intervention, greater weight loss, and shorter diabetes duration predict the best outcomes.
• Lifestyle medicine — nutrition, fasting, exercise, sleep — is the therapeutic foundation.

If you have been diagnosed with Type 2 diabetes or prediabetes, you have almost certainly seen the term HbA1c on your blood test results. It is the most important single number in diabetes management — more informative than fasting glucose, more predictive of complications, and the primary target of every treatment decision. Yet many patients leave the clinic not fully understanding what it measures, what their target should be, or how to move it in the right direction.

What Does HbA1c Actually Measure?

HbA1c stands for glycated haemoglobin. Haemoglobin is the protein inside red blood cells that carries oxygen. When glucose circulates in the blood, it attaches irreversibly to haemoglobin molecules through a non-enzymatic process called glycation. The higher your blood glucose over time, the greater the proportion of haemoglobin that becomes glycated.

Because red blood cells have a lifespan of approximately 90–120 days, HbA1c reflects the average blood glucose concentration over the preceding 2–3 months.^[1] This is what makes it so clinically valuable: it cannot be manipulated by a single day of dietary restriction before a test, as a fasting glucose can be.

HbA1c is reported either as a percentage (the NGSP/DCCT standard used in the USA and many other countries) or in mmol/mol (the IFCC standard used increasingly in the UK and Europe). A value of 6.5% is equivalent to 48 mmol/mol.

The Diagnostic and Target Thresholds

The World Health Organization and the American Diabetes Association define the HbA1c thresholds as follows:^[2,3]

• Below 5.7% (39 mmol/mol): Normal
• 5.7–6.4% (39–47 mmol/mol): Prediabetes (impaired glucose regulation)
• 6.5% (48 mmol/mol) or above: Diagnostic of Type 2 diabetes on two separate occasions
• Below 6.5% for 3+ months without medication: Remission of Type 2 diabetes^[4]

For patients already diagnosed with Type 2 diabetes, the general treatment target is HbA1c below 7.0% (53 mmol/mol), though this is individualised based on age, cardiovascular risk, hypoglycaemia risk, and the patient’s own goals.^[2] Tighter targets of below 6.5% are appropriate for younger patients, those recently diagnosed, and those with low hypoglycaemia risk.

Why Fasting Glucose Alone Is Insufficient

Many patients ask: “My fasting glucose was normal — so why is my HbA1c elevated?” The answer lies in postprandial glucose excursions — the spikes in blood sugar that occur after meals. Fasting glucose measures only the overnight baseline. It can appear entirely normal while post-meal glucose regularly spikes above 10–12 mmol/L (180–216 mg/dL), causing significant HbA1c elevation and driving microvascular complications.

Continuous Glucose Monitor (CGM) studies have demonstrated that in patients with normal fasting glucose but prediabetes-range HbA1c, post-meal glucose patterns are the primary driver of glycated haemoglobin.^[5] This is why we use fasting glucose, HbA1c, and fasting insulin together in a complete metabolic assessment — not any single marker in isolation.

HbA1c and Complication Risk: The Numbers That Matter

The landmark UK Prospective Diabetes Study (UKPDS) established the relationship between HbA1c and diabetic complication rates with precision. The key findings:^[6]

• Each 1% reduction in HbA1c is associated with a 37% reduction in microvascular complications (retinopathy, nephropathy, neuropathy).
• Each 1% reduction is associated with a 14% reduction in myocardial infarction.
• There is no lower threshold of benefit — lower is better, within safe limits.

This dose-response relationship is why we do not accept an HbA1c of 8% as “acceptable” in our patients. Every percentage point above target carries a quantifiable increase in complication risk.

Limitations of HbA1c: When It Can Mislead

HbA1c is reliable in most clinical situations, but several conditions can cause falsely low or falsely high readings:^[7]

• Falsely low: Haemolytic anaemia (shorter RBC lifespan), iron deficiency anaemia treatment (new RBCs dilute glycated cells), haemoglobinopathies (HbS, HbC), chronic blood loss.
• Falsely high: Iron deficiency anaemia (before treatment), vitamin B12/folate deficiency, splenectomy (longer RBC lifespan), chronic alcohol use.

In patients with these conditions, fructosamine (a 2–3 week average of glucose) or CGM-derived glucose management indicator (GMI) are preferred alternatives.

How to Reduce Your HbA1c: The Evidence-Based Hierarchy

The most effective interventions for HbA1c reduction, ranked by average HbA1c reduction achieved in clinical trials:^[8]

1. Significant weight loss (15%+ body weight): 2.0–3.0% reduction. The most powerful single intervention.^[9]
2. Low-carbohydrate diet (<130g carbs/day): 0.9–1.5% reduction at 6 months.^[10]
3. Time-restricted eating (16:8): 0.4–0.8% reduction, comparable to metformin in some trials.^[11]
4. Structured exercise (150 min/week aerobic + resistance): 0.5–0.7% reduction.^[12]
5. Metformin: 1.0–1.5% reduction on average.^[2]
6. SGLT2 inhibitors: 0.7–1.0% reduction, with additional cardiovascular and renal benefits.^[13]

Dr. Ahmed’s Approach: 8-Week Monitoring Intervals

At SehaTalks, we measure HbA1c at baseline and every 8 weeks during the active phase of our metabolic programme. This 8-week interval — rather than the standard 3-month interval — allows earlier detection of response, faster medication adjustment, and stronger patient motivation through visible progress. Most patients in our programme see their first HbA1c improvement within the first 8-week cycle.

Key Takeaways

• HbA1c reflects your average blood glucose over the past 2–3 months.
• Diagnosis threshold is 6.5% (48 mmol/mol); treatment target for most patients is below 7.0%.
• Fasting glucose alone misses post-meal spikes that drive HbA1c elevation.
• Each 1% HbA1c reduction reduces microvascular complication risk by 37%.
• Weight loss, low-carbohydrate diet, and time-restricted eating are the most powerful non-pharmacological interventions.

Insulin resistance is arguably the most consequential metabolic disturbance of our time. It precedes Type 2 diabetes by 10–15 years, underlies non-alcoholic fatty liver disease, polycystic ovary syndrome, hypertension, dyslipidaemia, and accelerates cardiovascular disease. Most people develop it silently, without any symptoms, while their routine fasting glucose remains in the normal range. Understanding insulin resistance — what it is, how to measure it, and how to reverse it — is foundational to preventive metabolic medicine.

What Is Insulin Resistance?

Insulin is a peptide hormone secreted by pancreatic beta cells in response to rising blood glucose. Its primary role is to facilitate glucose uptake into cells — particularly skeletal muscle (which accounts for 75–80% of post-meal glucose disposal), the liver (which stores glucose as glycogen), and adipose tissue (which uses glucose for triglyceride synthesis).^[1]

Insulin resistance develops when these target tissues lose their sensitivity to insulin signalling. The insulin receptor is still present, but the downstream intracellular signalling cascade — involving IRS-1 phosphorylation, PI3K activation, and GLUT4 translocation to the cell membrane — becomes impaired.^[2] The cell no longer efficiently extracts glucose from the bloodstream in response to normal insulin concentrations.

The pancreas compensates by secreting more insulin — a state called hyperinsulinaemia. For years, blood glucose appears normal because the pancreas is producing 2–5 times the usual amount of insulin to maintain it. It is only when beta cells can no longer sustain this compensation that fasting glucose rises and diabetes is diagnosed. But the underlying metabolic derangement has been present for over a decade.^[3]

The Upstream Causes of Insulin Resistance

Insulin resistance is driven by a convergence of factors:

• Ectopic fat accumulation: Excess lipid deposition in the liver (hepatic steatosis) and skeletal muscle interferes directly with insulin signalling by activating protein kinase C isoforms that phosphorylate IRS-1 on serine residues rather than tyrosine, impairing the signalling cascade.^[4]
• Chronic low-grade inflammation: Visceral adipose tissue secretes pro-inflammatory cytokines — TNF-α and IL-6 in particular — that directly inhibit insulin receptor signalling in muscle and liver.^[5]
• Mitochondrial dysfunction: Impaired mitochondrial oxidative capacity in skeletal muscle reduces the ability to oxidise fatty acids, leading to intramyocellular lipid accumulation and insulin resistance.^[6]
• Gut microbiome dysbiosis: Altered gut microbiota composition affects short-chain fatty acid production, intestinal permeability (increasing LPS translocation and systemic inflammation), and bile acid metabolism — all of which modulate insulin sensitivity.^[7]
• Sleep deprivation and cortisol excess: A single night of 4 hours of sleep raises cortisol sufficiently to reduce peripheral insulin sensitivity by 30–40% the following day.^[8]

The Downstream Cascade: What Hyperinsulinaemia Does

Chronically elevated insulin has profound systemic consequences beyond glucose dysregulation:^[9,10]

• Visceral fat accumulation: Insulin is a potent anabolic hormone that promotes fat storage, particularly in visceral depots which express high concentrations of insulin receptors.
• Dyslipidaemia: Hyperinsulinaemia stimulates hepatic VLDL-triglyceride production, raises small dense LDL particles, and suppresses HDL.
• Hypertension: Insulin promotes renal sodium retention and activates the sympathetic nervous system, raising blood pressure.
• PCOS: Hyperinsulinaemia stimulates ovarian androgen production, disrupting the LH/FSH ratio and driving the hormonal profile of polycystic ovary syndrome.
• Non-alcoholic fatty liver disease: Hepatic insulin resistance drives excess de novo lipogenesis in the liver.
• Cancer risk: Insulin and IGF-1 are potent mitogenic signals. Chronic hyperinsulinaemia has been associated with increased risk of breast, colorectal, endometrial, and pancreatic cancers.^[11]

Measuring Insulin Resistance: The HOMA-IR Score

The gold standard for measuring insulin resistance is the hyperinsulinaemic-euglycaemic clamp, a technically demanding research procedure. For clinical practice, HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is the validated surrogate:^[12]

HOMA-IR = (Fasting Insulin [mIU/L] × Fasting Glucose [mmol/L]) ÷ 22.5

Or in mg/dL units: HOMA-IR = (Fasting Insulin × Fasting Glucose) ÷ 405

Interpretation: Below 1.0 is optimal; 1.0–2.0 is normal; 2.0–2.5 is borderline; above 2.5 is significant insulin resistance requiring intervention. HOMA-IR above 3.0 correlates strongly with metabolic syndrome and predictsa 5–10 times higher risk of developing Type 2 diabetes within 5 years.^[13]

Importantly, HOMA-IR detects insulin resistance years before HbA1c or fasting glucose become abnormal. We routinely test fasting insulin as part of our metabolic panel — a test that is conspicuously absent from most standard annual health checks.

Reversing Insulin Resistance: The Evidence-Based Interventions

Insulin resistance is highly responsive to lifestyle intervention. The interventions with the strongest evidence, ranked by magnitude of HOMA-IR reduction in clinical trials:

1. Significant weight loss (10%+ body weight): Reduces HOMA-IR by 40–60% through reduction of ectopic fat and visceral adiposity.^[14]
2. Progressive resistance training: Increases GLUT4 expression in skeletal muscle independently of weight loss, improving insulin-mediated glucose disposal by 25–40%.^[15]
3. Low-carbohydrate diet (<130g/day): Reduces postprandial insulin demand directly; HOMA-IR reductions of 30–45% reported at 12 weeks.^[16]
4. Time-restricted eating: Improves insulin sensitivity through circadian alignment of glucose metabolism; HOMA-IR reductions of 15–25% at 12 weeks.^[17]
5. Sleep optimisation (7–9 hours): Reverses cortisol-mediated insulin resistance within days of improved sleep quality.^[8]
6. Metformin: Reduces hepatic glucose output; 15–20% HOMA-IR reduction. Useful adjunct but inferior to lifestyle change as monotherapy.^[18]

Body fat is not simply an inert energy store. It is a biologically active endocrine organ that secretes hormones, inflammatory cytokines, and free fatty acids — and its health consequences depend critically on where it is located. Visceral fat — the fat that wraps around abdominal organs — is metabolically aggressive, pro-inflammatory, and the primary driver of metabolic syndrome, insulin resistance, cardiovascular disease, and Type 2 diabetes. Subcutaneous fat — the fat under the skin — is comparatively benign. Understanding this distinction is fundamental to accurate cardiometabolic risk assessment.

Two Fat Compartments: Anatomy and Biology

The human body stores fat in two principal anatomical compartments:

Subcutaneous adipose tissue (SAT) lies directly beneath the dermis, distributed across the thighs, buttocks, upper arms, and trunk. It comprises approximately 80–85% of total body fat in most individuals. SAT functions primarily as a long-term energy reserve and provides thermal insulation and mechanical cushioning. SAT adipocytes produce leptin, adiponectin, and estrogen precursors — hormones with largely beneficial metabolic effects.^[1]

Visceral adipose tissue (VAT) is located within the abdominal cavity: the omentum (the large fat apron in the peritoneum), mesenteric fat (around the intestines), and peri-organ fat around the liver, pancreas, and kidneys. Despite comprising only 10–20% of total body fat, VAT exerts a disproportionate metabolic influence due to its anatomical location, distinct cellular biology, and direct drainage into the portal circulation.^[2]

The Portal Drainage Hypothesis: Why VAT Location Is So Dangerous

The anatomical key to VAT’s metabolic danger is its venous drainage. Unlike subcutaneous fat, which drains into the systemic circulation, visceral fat drains directly via the portal vein into the liver. This means that all the free fatty acids (FFAs), cytokines, and adipokines released by visceral adipocytes arrive directly at the liver in high concentration, before dilution in systemic circulation.^[3]

This portal FFA flux drives:^[4]

• Hepatic insulin resistance: Excess FFA delivery activates hepatic protein kinase C-ε, impairing insulin receptor signalling and driving excess hepatic glucose output.
• Non-alcoholic fatty liver disease (NAFLD/MASLD): The liver’s limited capacity to oxidise the FFA flux leads to triglyceride accumulation within hepatocytes.
• VLDL overproduction: The liver exports excess lipid as VLDL-triglycerides, raising plasma triglycerides and promoting small dense LDL formation.
• Hyperinsulinaemia: To overcome hepatic insulin resistance, the pancreas secretes more insulin, creating a systemic hyperinsulinaemic state with all its downstream consequences.

Visceral Fat as an Endocrine Organ: The Adipokine Cascade

Visceral adipocytes have a distinct secretory profile compared to subcutaneous adipocytes. They produce:^[5,6]

• TNF-α (tumour necrosis factor-alpha): A pro-inflammatory cytokine that inhibits insulin receptor signalling and promotes apoptosis. VAT secretes 5–10 times more TNF-α per gram than SAT.
• IL-6 (interleukin-6): Drives hepatic CRP production, promoting systemic inflammation and endothelial dysfunction.
• PAI-1 (plasminogen activator inhibitor-1): Impairs fibrinolysis, increasing thrombosis risk and contributing to cardiovascular events.
• Resistin: Promotes insulin resistance in hepatic and skeletal muscle tissue.
• Reduced adiponectin: Unlike the above, adiponectin is protective — it improves insulin sensitivity, reduces hepatic fat, and has anti-inflammatory effects. Visceral obesity is associated with paradoxically low adiponectin despite abundant fat mass.

The Metabolically Obese Normal Weight (MONW) Phenotype

Perhaps the most clinically important implication of the VAT-SAT distinction is the existence of metabolically obese normal weight (MONW) individuals — people with BMI in the normal range who nonetheless carry significant visceral fat and display full metabolic syndrome.^[7] This phenotype is particularly prevalent in South Asian, East Asian, and Middle Eastern populations, who carry higher proportions of visceral fat at any given BMI compared to European populations.

Conversely, the metabolically healthy obese (MHO) phenotype describes individuals with high BMI who carry their excess fat predominantly subcutaneously, with comparatively low visceral fat and preserved insulin sensitivity. Though MHO status is not fully protective and tends to deteriorate with age, these individuals have dramatically lower short-term metabolic risk than those with equivalent BMI but high VAT.^[8]

Measuring Visceral Fat: From Simple to Precise

Measurement options, from least to most precise:^[9]

1. Waist circumference: The simplest proxy. In South Asian and Middle Eastern populations, cardiometabolic risk rises at waist circumferences above 90cm (men) and 80cm (women) — significantly lower than the Western thresholds of 102cm/88cm.
2. Waist-to-height ratio: A waist circumference above 50% of height is a reliable indicator of elevated visceral fat risk across all ethnicities.
3. Waist-to-hip ratio: Ratio above 0.90 (men) or 0.85 (women) indicates central adiposity.
4. DEXA scan (dual-energy X-ray absorptiometry): Provides precise fat distribution data, distinguishing VAT and SAT compartments.
5. Abdominal MRI or CT: The gold standard for visceral fat quantification in research settings.

Reducing Visceral Fat: What Works

Visceral fat is more responsive to caloric restriction and exercise than subcutaneous fat. Targeted reductions:^[10,11]

• Caloric restriction: VAT is preferentially mobilised in the first weeks of caloric restriction. A 5% total body weight loss produces a 10–15% reduction in visceral fat volume.
• Aerobic exercise: Even without weight loss, 30 minutes of moderate aerobic exercise 5 days per week reduces visceral fat by 3–6% over 12 weeks.
• Resistance training: Reduces VAT through improved insulin sensitivity and increased resting metabolic rate.
• Sleep: As discussed in our sleep article, inadequate sleep specifically promotes visceral fat accumulation via cortisol dysregulation.
• SGLT2 inhibitors and GLP-1 agonists: Both drug classes preferentially reduce visceral fat disproportionately to overall weight loss.

A comprehensive metabolic blood panel is the most powerful window into your long-term health trajectory. Yet most patients receive their results with a brief “everything looks normal” — without any explanation of what each value means, how the values relate to one another, or what actions to take. This guide provides a detailed walkthrough of every major metabolic marker, explaining clinical significance, optimal targets, and the interventions that move each parameter in the right direction.

Glucose Metabolism Markers

Fasting Glucose

A 8–12 hour fasted blood glucose reflects primarily hepatic glucose output overnight. Normal is below 5.6 mmol/L (100 mg/dL). Impaired fasting glucose (IFG) is 5.6–6.9 mmol/L; diabetic range is 7.0 mmol/L or above on two occasions.^[1] Limitation: a normal fasting glucose does not rule out post-meal glucose dysregulation or significant insulin resistance (see HOMA-IR below).

HbA1c (Glycated Haemoglobin)

Reflects average blood glucose over 2–3 months. Normal below 5.7% (39 mmol/mol); prediabetes 5.7–6.4%; diabetes 6.5% and above. Treatment target for most patients with T2D: below 7.0%. For remission: below 6.5% without medication for 3+ months.^[2]

Fasting Insulin and HOMA-IR

Fasting insulin is routinely absent from standard blood panels but is arguably the most important early metabolic marker. Reference range for fasting insulin: 2–25 mIU/L, with an optimal level below 8 mIU/L in metabolically healthy individuals.^[3] HOMA-IR (Fasting Insulin × Fasting Glucose ÷ 22.5) above 2.5 indicates significant insulin resistance requiring intervention. We test this in every patient at SehaTalks.

Fructosamine

Fructosamine measures glycated serum proteins, reflecting average glucose over the preceding 2–3 weeks. Useful when HbA1c is unreliable (haemoglobinopathies, haemolysis, iron deficiency). Reference range: 205–285 μmol/L.^[4]

Lipid Markers

Total Cholesterol

Total cholesterol (TC) is the sum of all cholesterol-carrying lipoprotein particles. It is a poor standalone cardiovascular risk predictor — its utility is primarily in calculating other ratios. Desirable TC: below 5.2 mmol/L (200 mg/dL).^[5]

LDL Cholesterol

Low-density lipoprotein cholesterol is the primary pharmacological treatment target. However, LDL-C measures the cholesterol content within LDL particles, not the number of particles. Optimal LDL-C: below 2.6 mmol/L (100 mg/dL) for primary prevention; below 1.8 mmol/L (70 mg/dL) for high-risk patients; below 1.4 mmol/L (55 mg/dL) for very high-risk patients (established ASCVD).^[6]

HDL Cholesterol

HDL-C (high-density lipoprotein cholesterol) is the primary marker of reverse cholesterol transport capacity. Low HDL-C (below 1.0 mmol/L [40 mg/dL] in men, below 1.3 mmol/L [50 mg/dL] in women) is a major cardiovascular risk factor and a strong marker of insulin resistance. Raising HDL through lifestyle: exercise (particularly aerobic) raises HDL by 5–10%; eliminating smoking raises HDL by 10%; reducing refined carbohydrate raises HDL through lowering triglycerides.^[5]

Triglycerides

Fasting triglycerides reflect primarily hepatic VLDL secretion, which is driven by excess carbohydrate intake, insulin resistance, and alcohol. Target: below 1.7 mmol/L (150 mg/dL). Optimal for metabolic health: below 1.1 mmol/L (100 mg/dL). Fasting triglycerides above 2.0 mmol/L (175 mg/dL) indicate significant metabolic dysfunction requiring dietary intervention regardless of LDL-C levels.^[7]

Triglyceride-to-HDL Ratio

As covered in our lipid panel article, this ratio is the most clinically practical screen for small dense LDL predominance and insulin resistance. Optimal: below 1.0 (mmol/L units) or below 2.0 (mg/dL units). Above 1.5 (mmol/L) warrants investigation for insulin resistance.^[8]

Non-HDL Cholesterol

Total Cholesterol minus HDL-C. Captures all atherogenic particles. Target: below 3.4 mmol/L (131 mg/dL) for general population; below 2.6 mmol/L (100 mg/dL) for high-risk patients.^[5]

Apolipoprotein B (ApoB)

One ApoB per atherogenic particle — the most accurate measure of atherogenic particle burden. Target: below 0.9 g/L for primary prevention; below 0.7 g/L for high-risk patients.^[9]

Liver Enzymes

ALT (Alanine Aminotransferase)

ALT is the most specific marker of hepatocellular injury. Elevated ALT indicates hepatic inflammation, most commonly from non-alcoholic fatty liver disease (NAFLD/MASLD) in the metabolic patient. Importantly, the traditional laboratory upper limit of normal (45 U/L in many labs) is too permissive: population studies demonstrate that ALT above 30 U/L in men and 19 U/L in women correlates with significant hepatic steatosis, even within the “normal” range.^[10] We use these stricter thresholds in clinical practice.

AST (Aspartate Aminotransferase)

AST is less specific than ALT but provides additional information. An AST:ALT ratio above 2:1 suggests alcoholic liver disease rather than NAFLD. An AST:ALT ratio below 1 is typical of early NAFLD.^[11]

GGT (Gamma-Glutamyltransferase)

GGT is a sensitive marker of hepatic oxidative stress, bile duct dysfunction, and alcohol intake. Even mildly elevated GGT (above 30 U/L in women, 50 U/L in men) is associated with significantly higher all-cause mortality and cardiovascular risk, independent of alcohol intake.^[12]

Kidney Function

Creatinine and eGFR

Serum creatinine is a byproduct of muscle metabolism, filtered by the glomerulus. eGFR (estimated GFR) is calculated from creatinine, age, sex, and race. CKD is defined as eGFR below 60 for 3+ months, or evidence of structural or functional kidney abnormality. Creatinine is unreliable in low-muscle-mass individuals; cystatin C provides a more accurate eGFR in these cases.^[13]

Urine Albumin-to-Creatinine Ratio (UACR)

The most sensitive early marker of diabetic kidney disease. Should be measured annually in all patients with Type 2 diabetes from the time of diagnosis. Microalbuminuria (UACR 3–30 mg/mmol) is the earliest detectable sign of glomerular injury and is highly reversible with optimal metabolic control and RAS blockade.^[14]

Inflammation and Thyroid

hsCRP (High-Sensitivity C-Reactive Protein)

CRP is the liver’s acute phase reactant, driven by IL-6 from visceral adipose tissue and other inflammatory sources. In the context of metabolic disease, hsCRP is a marker of visceral fat burden and cardiovascular risk. Below 1.0 mg/L: low risk. 1.0–3.0 mg/L: average risk. Above 3.0 mg/L: high risk. The JUPITER trial demonstrated that patients with low LDL but elevated hsCRP achieved significant cardiovascular risk reduction with statin therapy, establishing hsCRP as an independent treatment trigger.^[15]

TSH (Thyroid Stimulating Hormone)

Hypothyroidism raises LDL cholesterol, promotes weight gain, causes fatigue, and impairs metabolic rate — perfectly mimicking metabolic syndrome. TSH should be tested in every patient presenting with dyslipidaemia, unexplained weight gain, or fatigue. Optimal TSH: 0.5–2.5 mIU/L; values above 4.0 mIU/L indicate hypothyroidism in symptomatic patients.^[16]